Introduction {#s1}
============

Pancreatic cancer (PC) is the second most common gastrointestinal malignancy and the fourth leading cause of cancer death worldwide ([@B1]). As one of the most lethal and challenging malignancies, PC has a dismal prognosis with a 5-year survival rate of only 8% ([@B2]). Surgical resection remains the only curative modality for patients with PC. However, most of the patients were diagnosed at advanced stages and the surgical resection rate was only 20% ([@B3], [@B4]) because of metastasis (40%) or involvement of major vascular structures (40%), such as celiac artery, hepatic artery, superior mesenteric artery, and other structures of the portovenous axis ([@B5]). Locally advanced pancreatic cancer (LAPC) evolves without evidence of distant metastasis and, on macroscopic level, is represented with surrounding vascular involvement ([@B6]). A typical treatment which begins with system therapy to control micrometastatic diseases followed by radiation for local control may provide the best benefit for these patients. Previously, the management of LAPC patients foresees the use of gemcitabine based on chemotherapy in association or not with radiotherapy, achieving marginal benefits in terms of elevating overall survival. Moreover, such multimodality therapy can only downstage a small proportion of patients to resectable diseases. Although FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) are used most recently as neoadjuvant setting for LAPC and have achieved improved survival, majority of LAPC patients remain ineligible for curative intent of surgical resection ([@B6]). In addition, patients with unresectable LAPC indeed own a poor median survival of only 6--11.5 months in most of prospective clinical trials despite advances in chemotherapy, radiotherapy, and chemoradiotherapy ([@B7], [@B8]). In this term, apart from systemic chemotherapy and radiation therapy, a new therapy method should be explored to improve the prognosis of LAPC patients.

Patients with local advanced, albeit unresectable PC should theoretically benefit from maximal local therapy. As a novel ablative procedure, irreversible electroporation (IRE) is a potential solution for the treatment of LAPC, which was widely performed intraoperatively ([@B9]), laparoscopically ([@B10]), or percutaneously ([@B11]) since 2009 ([@B12]). Instead of causing a thermal-based coagulative necrosis, IRE induces permanent cell membrane porosity by high-voltage and microsecond-length pulses, which causes permanent cell death without the destruction of the nearby structure ([@B13]--[@B15]). This unique feature of procedure makes IRE an ideal palliative treatment for LAPC patients, with surprisingly prolonged survival ([@B16]). With more and more use of this treatment, it is necessary to identify the clinical and pathological features of LAPC patients who received IRE treatment. Moreover, the most frequently used stage system, the 8th edition Tumor-Node-Metastasis (TNM) stage system of the American Joint Commission on Cancer (AJCC) ([@B17]), only focuses some of the pathological factors, ignoring some other potential variables, such as age and tumor grade. It is believed that the individual prognostic stage based on personal evaluation of prognostic factors is more helpful for personalized treatment. Therefore, it is necessary to establish specialized prognostic-stage systems to stratify the prognosis of LAPC patients after IRE treatment.

In addition, most of the included patients are diagnosed at their old ages. The negative impacts of the increasing ages on organ function and the varieties of age-related comorbidities, which are considered as competing risk events, may dilute or negate the benefit of the treatment ([@B18]). Therefore, it is important to consider the competing risks when evaluating prognosis. However, to our knowledge, there are no prognostic-stage systems considering both overall survival (OS) and cancer-specific survival (CSS) for LAPC patients after IRE on the basis of population-based data.

In the present study, survival exploration of LAPC patients based on OS analysis and competing risk analyses was conducted with the Surveillance, Epidemiology, and End Results (SEER) database, and the nomograms were established to estimate rates of OS and CSS for LAPC patients after IRE treatment.

Patients and Methods {#s2}
====================

Patients
--------

Data of LAPC patients after IRE were extracted from the SEER database from 2012 to 2015, using the SEER^\*^Stat software version 8.3.5. The study cohort consisted of patients with the following International Classification of Diseases for Oncology, Third Edition (ICD-O-3), histology codes 8010/3, 8021/3, 8140/3, 8255/3, and 8263/3, and the ICD-O-3 site codes C25.1, C25.2, C25.3, and C25.8. The following patients were excluded from this study: (1) patients with second primary cancer; (2) patients who were younger than 18 years; (3) patients not radiologically and pathologically diagnosed of LAPC; (4) patients who had received treatments other than IRE, including resection and radiotherapy; (5) patients whose information of survival, follow-up, or other factors were incomplete; and (6) patients with distant metastases or those whose tumor was not classified as T4 stage. Patients were randomly selected to serve as the training and internal validation cohorts in a ratio of 2:1. The second cohort of patients was from the Sun Yat-sen University Cancer Center (SYSUCC) (2015--2019). The exclusion criteria were the same as in our previous study ([@B19]). The patients from the SYSUCC database were used as the external validation cohort.

Data Collection
---------------

The clinical variables, such as age, gender, and chemotherapy, and clinical and pathological variables of patients, including tumor site, grade, size, TNM stage, follow-up information, and cause of death, were extracted from the SEER database and SYSUCC database. Seventy years was used as the cutoff value for age at diagnosis. OS, CSS, and non-cancer-specific survival (NCSS) were defined as the duration from the date of treatment to death due to all causes, cancer and other causes, and last follow-up, respectively.

Statistical Analysis
--------------------

The probability of cancer-specific and non-cancer-specific death was evaluated by the cumulative incidence function (CIF) and compared by Gray\'s test ([@B20]). OS was analyzed using the Kaplan--Meier method and compared by the log-rank test. The hazard ratio (HR) and the associated 95% confidence interval (CI) were calculated. The Fine and Gray\'s model ([@B21]) and Cox regression model were used to build the competing risk nomograms and the nomogram for predicting OS. The established nomograms were calibrated with calibration curves and evaluated by concordance index (C-index) and the area under ROC curves (AUC) ([@B22], [@B23]).

R version 3.4.2 software (The R Foundation for Statistical Computing, Vienna, Austria, <http://www.r-project.org>) was used for statistical analyses. A two-tailed *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Patient Characteristics
-----------------------

We identified 237 eligible LAPC patients who had received IRE treatment from the SEER database. In addition, consecutive LAPC patients who were initially treated with IRE between 2015 and 2019 at the Department of Pancreatobiliary Surgery of SYSUCC were also enrolled in this study. The flow diagram of the data selection is shown in [Figure 1](#F1){ref-type="fig"}. There were 158 patients in the training cohort and 79 patients in the internal validation cohort. Another 75 patients from the SYSUCC database were used as an external validation cohort. The included patients had a median age of 66 years (range 26--93 years). Female patients (123, 51.9%) were a little more than male patients (114, 48.1%). The head of pancreas (70.8%) was the most common tumor site, followed by the tail (13.9%), the body (10.1%), and the overlapping sites of the pancreas (5.2%). A majority of patients (154, 49.7%) had tumors which were poorly differentiated. As for tumor size, the large size (lager than 4 cm, 45.6%) was the most common, followed by median size (2--4 cm, 43.9%) and small size (smaller than 2 cm, 10.5%). More than half of patients had received chemotherapy in both training and validation cohorts ([Table 1](#T1){ref-type="table"}).

![Flow diagram of the data selection process.](fonc-10-00952-g0001){#F1}

###### 

The comparison of clinicopathological factors between training cohort and validation cohort.

  **Characteristic**   ***N***                         **Patients**   ***P***        
  -------------------- ------------------------------- -------------- --------- ---- -------
  Total                                                237            158       79   
  Age (years)          \<70                            137            93        44   0.677
                       ≥70                             100            65        35   
  Gender               Male                            114            79        35   0.491
                       Female                          123            79        44   
  Chemotherapy         No                              101            62        39   0.164
                       Yes                             136            96        40   
  Tumor site           Head                            168            113       55   0.491
                       Body                            24             18        6    
                       Tail                            33             21        12   
                       Overlapping sites               12             6         6    
  Tumor size (cm)      ≤2                              24             17        7    0.228
                       2--4                            104            63        41   
                       \>4                             108            77        31   
  Tumor grade          Well                            17             11        6    0.928
                       Moderate                        66             43        23   
                       Poor                            154            104       50   
  Survival status      Survival                        14             11        3    0.385
                       Cancer-specific mortality       170            115       55   
                       Non-cancer-specific mortality   53             32        21   

In the present study, there were 170 deaths due to LAPC and 53 deaths due to other causes during the follow-up period with 8 months (range, 1--186 months) as the median time. The comparison of 1-, 2-, and 3-year OS rates, cancer-specific mortalities, and non-cancer-specific mortalities is summarized in [Table 2](#T2){ref-type="table"}. The corresponding CIF curves according to different features are shown in [Figure 2](#F2){ref-type="fig"}. In the whole group, the 1-, 2-, and 3-year cumulative incidences of all-cause death were 66.7, 73.0, and 74.3%, respectively. There were no significant differences in cancer-specific and non-cancer-specific mortalities between male and female patients. Patients of older ages had significantly higher non-cancer-specific mortalities compared with the younger ones while the cancer-specific mortalities were comparable between these two groups. Chemotherapy contributed to significantly decreased mortality while it did not show a closed relationship with non-cancer-specific mortality. Compared with well-differentiated disease, patients with moderately or poorly differentiated tumors did not have significantly higher cancer-specific mortalities. Tumor site and tumor size did not predict the probability of cancer-specific mortality in LAPC patients after IRE treatment. Other than age, patients whose tumor was smaller than 2 cm had significant higher non-cancer-specific mortality ([Table 2](#T2){ref-type="table"}).

###### 

Overall survival rates and cumulative incidences of mortality among patients with LAPC after IRE treatment.

  **Characteristic**   **Patients**        **Overall survival rate (%)**   ***P***   **Cancer-specific mortality (%)**   ***P***   **Non-cancer-specific mortality (%)**   ***P***                                                       
  -------------------- ------------------- ------------------------------- --------- ----------------------------------- --------- --------------------------------------- --------- ------ ------ ------ --------- ------ ------ ------ -------
  Total                                    237                             100       12.2                                3.8       2.5                                               66.7   73.0   74.3             21.1   23.2   23.2   
  Age (years)          \<70                137                             58        16.0                                4.6       4.6                                     \<0.001   67.7   75.7   75.7   0.893     16.2   19.7   19.7   0.049
                       ≥70                 100                             42        6.8                                 2.7       0                                                 65.4   69.5   NA               27.8   27.8   NA     
  Gender               Male                114                             48        14.0                                4.6       3.0                                     0.247     67.5   75.9   77.4   0.819     18.5   19.5   19.5   0.242
                       Female              123                             52        10.4                                3.1       2.1                                               65.9   70.1   71.2             23.6   26.8   26.8   
  Chemotherapy         No                  101                             43        0                                   0         0                                       \<0.001   NA     NA     NA     \<0.001   NA     NA     NA     0.665
                       Yes                 136                             57        21.5                                6.7       2.06                                              57.1   68.2   70.5             21.3   25.0   25.0   
  Tumor site           Head                168                             71        13.8                                2.0       2.0                                     0.504     70.0   80.2   80.2   0.354     16.2   17.8   17.8   0.436
                       Body                24                              10        26.1                                13.1      6.5                                               43.1   49.7   56.2             30.7   37.3   37.3   
                       Tail                33                              14        13.3                                3.3       3.3                                               66.7   76.7   NA               20.0   20.0   NA     
                       Overlapping sites   12                              5         8.3                                 0         0                                                 75.0   NA     NA               16.7   NA     NA     
  Tumor size (cm)      ≤2                  24                              10        41.4                                13.2      8.8                                     0.025     28.6   NA     NA     0.413     71.4   NA     NA     0.001
                       2--4                104                             44        30.6                                0         0                                                 40.4   61.1   65.5             18.2   25.7   25.7   
                       \>4                 108                             46        0                                   0         0                                                 48.3   NA     NA               21.1   NA     NA     
  Tumor grade          Well                17                              7         26.7                                0         0                                       0.436     60.0   NA     NA     0.748     13.3   NA     NA     0.756
                       Moderate            66                              28        8.0                                 4.0       2.0                                               72.0   74.0   74.0             20.0   22.0   22.0   
                       Poor                154                             65        11.8                                4.0       4.0                                               69.7   77.6   77.6             18.4   18.4   18.4   

*LAPC, locally advanced pancreatic cancer; IRE, irreversible electroporation; NA, not available*.

![Cumulative mortality curves regarding cancer-specific and competing mortality stratified by patient characteristics: **(A)** age; **(B)** gender; **(C)** chemotherapy; **(D)** tumor site; **(E)** tumor size; **(F)** tumor grade.](fonc-10-00952-g0002){#F2}

OS and CSS of Patients
----------------------

According to the results of the OS analyses which are shown in [Figure 3](#F3){ref-type="fig"}, OS rates of patients were significantly different when they were stratified by age, tumor size, and chemotherapy. There were no obvious differences in OS rates of patients when they were stratified by gender, tumor site, and tumor grade. Moreover, the univariate analysis revealed that age, tumor site, tumor size, tumor grade, and chemotherapy were all significantly associated with OS. These variables were then analyzed by multivariate analysis to delineate various prognostic indicators. It was shown that age (HR = 1.226, 95% CI, 1.101--1.987, *P* = 0.042), tumor site (HR = 1.647, 95% CI, 1.124--2.145, *P* = 0.023), tumor size (HR = 2.337, 95% CI, 1.684--3.114, *P* = 0.004), tumor grade (HR = 1.877, 95% CI, 1.442--2.482, *P* = 0.014), and chemotherapy (HR = 0.273, 95% CI, 0.121--0.367, *P* = 0.001) could strongly predict OS. Proportional subdistribution hazard assumption was held for variables used for CSS analysis. Age, tumor size, tumor grade, and chemotherapy were all independently associated with CSS. Moreover, age, tumor site, and tumor size were proved to be significantly related to NCSS ([Table 3](#T3){ref-type="table"}).

![Kaplan--Meier OS curves stratified by patient characteristics: **(A)** age; **(B)** gender; **(C)** chemotherapy; **(D)** tumor site; **(E)** tumor size; **(F)** tumor grade.](fonc-10-00952-g0003){#F3}

###### 

Univariate and multivariate analyses of survival in patients with PC after IRE treatment.

  **Characteristic**                **Overall survival**   **Cancer-specific survival**   **Non-cancer-specific survival**                                                                                                                                                      
  --------------------------------- ---------------------- ------------------------------ ---------------------------------- ------- -------------- ------- ------- -------------- ------- ------- -------------- ------- ------- -------------- ------- ------- -------------- -------
  Age (years)                                                                             0.003                                                     0.042                          0.047                          0.042                          0.011                          0.002
  \<70/≥70                          1.510                  1.153--1.977                                                      1.226   1.101--1.987           1.371   1.004--1.873           1.124   1.002--1.568           2.031   1.178--3.053           2.113   1.486--4.525   
  Gender                                                                                  0.296                                                     NI                             0.680                          NI                             0.163                          NI
  Male/female                       1.151                  0.884--1.498                                                                                     1.066   0.788--1.441                                          1.477   0.854--2.553                                  
  Chemotherapy                                                                            0.001                                                     0.001                          0.001                          0.001                          0.187                          NI
  No/yes                            0.285                  0.210--0.386                                                      0.273   0.121--0.367           0.243   0.170--0.346           0.223   0.143--0.355           0.457   0.248--1.142                                  
  Tumor site                                                                              0.034                                                     0.023                          0.045                          0.425                          0.049                          0.026
  Head/body/tail/overlapping site   1.086                  1.006--1.172                                                      1.647   1.124--2.145           1.061   1.001--1.158           1.124   0.748--1.232           1.170   1.001--1.368           1.416   1.043--1.921   
  Tumor size (cm)                                                                         0.002                                                     0.004                          0.012                          0.002                          0.002                          0.009
  ≤ 2/2--4/\>4                      2.564                  1.754--3.874                                                      2.337   1.684--3.114           2.547   1.625--3.335           2.744   1.562--3.587           0.177   0.060--0.523           0.230   0.076--0.694   
  Tumor grade                                                                                                                                       0.014                          0.002                          0.027                          0.010                          0.089
  Well/moderate/poor                1.614                  1.271--2.049                   0.001                              1.877   1.442--2.482           1.515   1.159--1.980           1.711   1.121--3.152           1.153   1.108--2.112           1.124   0.746--1.885   

*LN, lymph node; HR, hazard ratio; CI, confidence interval; NI, not included; other abbreviations as in [Table 2](#T2){ref-type="table"}*.

Construction and Validation of Nomograms
----------------------------------------

Nomograms were established with the independent predictors of OS, CSS, and NCSS ([Figure 4](#F4){ref-type="fig"}). By adding the scores for each selected variables, the established nomograms can be used to predict the probability of 1-, 2-, and 3-year OS, CSS, and NCSS for patients with LAPC after IRE treatment. The well-calibrated curves for nomograms were observed in both training and internal validation cohorts ([Figures 5](#F5){ref-type="fig"}--[7](#F7){ref-type="fig"}). The C-index of nomogram for OS prediction was 0.782 (95% CI, 0.759--0.806). The nomogram for CSS and NCSS prediction showed great predictive power with C-indexes of 0.729 (95% CI, 0.696--0.762) and 0.730 (95% CI, 0.679--0.781), respectively. In addition, compared with the 7th or 8th edition TNM stage system, the established nomograms showed higher values of C-indexes, indicating enhanced discriminatory ability in predicting OS, CSS, and NCSS ([Table 4](#T4){ref-type="table"}). To further illustrate the clinical use of the established nomograms, the nomograms were validated in the SYSUCC cohort, which was used as an external cohort. The C-indexes of the external cohort were 0.780 (95% CI, 0.723--0.837) for OS and 0.776 (95% CI, 0.700--0.852) for CSS, respectively, which were both higher than those of the 7th or 8th edition TNM stage system ([Table 4](#T4){ref-type="table"}).

![Nomograms predicting 1-, 2-, and 3-year OS **(A)**, CSS **(B)**, and NCSS **(C)** of patients with PC after IRE treatment. OS, overall survival; CSS, cancer-specific survival; NCSS, non-cancer-specific survival; PC, pancreatic cancer; IRE, irreversible electroporation.](fonc-10-00952-g0004){#F4}

![Calibration of the nomogram using the training **(A--C)** and validation cohorts **(D--F)** is shown. The x-axis represents the nomogram-predicted OS rate, and the y-axis represents the actual OS rate. OS, overall survival.](fonc-10-00952-g0005){#F5}

![Calibration of the nomogram using the training **(A--C)** and validation cohorts **(D--F)** is shown. The x-axis represents the nomogram-predicted CSS rate, and the y-axis represents the actual CSS rate. CSS, cancer-specific survival.](fonc-10-00952-g0006){#F6}

![Calibration of the nomogram using the training **(A--C)** and validation cohorts **(D--F)** is shown. The x-axis represents the nomogram-predicted NCSS rate, and the y-axis represents the actual NCSS rate. NCSS, non-cancer-specific survival.](fonc-10-00952-g0007){#F7}

###### 

C-indexes for the nomograms and TNM staging systems in patients with PC after IRE treatment.

  **Survival**                   **Training cohort**   ***P***                **Internal validation cohort**   ***P***                **External validation cohort**   ***P***                
  ------------------------------ --------------------- ---------------------- -------------------------------- ---------------------- -------------------------------- ---------------------- -----------
  Overall survival               Nomogram              0.782 (0.759--0.806)   Reference                        0.742 (0.683--0.801)   Reference                        0.780 (0.723--0.837)   Reference
                                 TNM 7th stage         0.490 (0.304--0.676)   \<0.001                          0.614 (0.566--0.662)   \<0.001                          0.528 (0.447--0.609)   \<0.001
                                 TNM 8th stage         0.604 (0.492--0.716)   0.021                            0.659 (0.614--0.704)   \<0.001                          0.530 (0.432--0.628)   \<0.001
  Cancer-specific survival       Nomogram              0.729 (0.696--0.762)   Reference                        0.737 (0.676--0.800)   Reference                        0.776 (0.701--0.852)   Reference
                                 TNM 7th stage         0.506 (0.390--0.622)   0.002                            0.627 (0.573--0.681)   \<0.001                          0.559(0.476--0.642)    \<0.001
                                 TNM 8th stage         0.636 (0.530--0.742)   0.198                            0.666 (0.613--0.719)   \<0.001                          0.569(0.470--0.668)    \<0.001
  Non-cancer-specific survival   Nomogram              0.730 (0.679--0.781)   Reference                        0.643 (0.516--0.770)   Reference                        NA                     NA
                                 TNM 7th stage         0.545 (0.377--0.713)   \<0.001                          0.622 (0.539--0.705)   0.008                            NA                     NA
                                 TNM 8th stage         0.481 (0.242--0.720)   \<0.001                          0.564 (0.473--0.655)   \<0.001                          NA                     NA

*Abbreviations as in [Table 2](#T2){ref-type="table"}, NA, not available*.

In addition, the comparison of AUC values of the stage systems is shown in [Figure 8](#F8){ref-type="fig"}. The AUC values of the nomograms for predicting 1-, 2-, and 3-year OS and CSS were 0.720, 0.720, and 0.768 and 0.720, 0.717, and 0.774, respectively, in the training cohort, which were higher than those of 7th and 8th TNM stage systems. Also, the AUC values of the nomograms on the external validation cohort for predicting 1-, 2-, and 3-year survival were 0.732 and 0.830, 0.756 and 0.762, and 0.698 and 0.696 for OS and CSS, respectively, which were all highest among those of different stage systems. Moreover, the established nomograms also showed superior discriminatory capacity in predicting NCSS in both training and validation cohorts ([Table 5](#T5){ref-type="table"}).

![Comparison of the values of AUC of the nomogram and the TNM staging systems for 1-, 2-, and 3-year OS prediction **(A,B)**, CSS prediction **(C,D)**, and NCSS prediction **(E,F)** in the training and validation cohorts. AUC, area under ROC curves; OS, overall survival; CSS, cancer-specific survival; NCSS, non-cancer-specific survival.](fonc-10-00952-g0008){#F8}

###### 

Values of AUC for the nomograms and TNM staging systems in patients with PC after IRE treatment.

  **Survival**                   **Training cohort**   **Internal validation cohort**   **External validation cohort**                                                   
  ------------------------------ --------------------- -------------------------------- -------------------------------- ------- ------- ------- ------- ------- ------- -------
  Overall survival               Nomogram              0.720                            0.720                            0.768   0.683   0.692   0.670   0.732   0.756   0.698
                                 TNM 7th stage         0.637                            0.649                            0.712   0.523   0.305   0.201   0.471   0.732   0.528
                                 TNM 8th stage         0.676                            0.701                            0.773   0.598   0.596   0.501   0.589   0.681   0.638
  Cancer-specific survival       Nomogram              0.720                            0.717                            0.774   0.623   0.682   0.648   0.830   0.762   0.696
                                 TNM 7th stage         0.637                            0.645                            0.710   0.483   0.315   0.208   0.477   0.754   0.538
                                 TNM 8th stage         0.674                            0.589                            0.775   0.512   0.567   0.454   0.663   0.707   0.646
  Non-cancer-specific survival   Nomogram              0.624                            0.583                            0.526   0.704   0.573   0.573   NA      NA      NA
                                 TNM 7th stage         0.579                            0.560                            0.560   0.597   0.446   0.446   NA      NA      NA
                                 TNM 8th stage         0.615                            0.608                            0.614   0.681   0.561   0.561   NA      NA      NA

*AUC, area under ROC curve; other abbreviations as in [Table 4](#T4){ref-type="table"}*.

Discussion {#s4}
==========

LAPC has a steadily increasing incidence rate and aggressive nature. The resectable rate at diagnosis is relatively low, and the involvement of the nearby vascular structures contributes to 30% of unresectable tumors ([@B5]). IRE is a novel method and has been proven to be an effective treatment for LAPC ([@B16]). Due to the variation of clinical and pathological features of LAPC patients after IRE treatment, it is imprecise to estimate prognosis for these patients relying on the traditional stage systems. It is necessary to evaluate the prognostic factors and establish an efficient stage system which is specially for these patients. Moreover, many patients were diagnosed at their older ages and the increasing ages might have an impact on their survival. However, previous stage systems only considered OS, ignoring to evaluate the prognostic impact of age ([@B24]--[@B26]). Thus, in this study, we sought to evaluate the demographic, clinical, and pathological features of LAPC patients after IRE treatment and establish prognostic nomograms to predict OS, CSS, and NCSS.

Similar to other studies ([@B27], [@B28]), most patients were nearly 70 years old when they were diagnosed with LAPC. It was observed that age was associated with OS, CSS, and NCSS. This means that older patients are at great risks of cancer-specific death and non-cancer-specific death. In addition, it was shown that the increasing age was proven to be an independent risk factor for long-term survival in this study, especially NCSS, for which age had displayed the greatest prognostic impact. This result was in agreement with that from other studies ([@B29], [@B30]). The age-related comorbid conditions played an important role in non-cancer-specific mortality. With this, it was a suitable method to take surgery tolerance into account to evaluate prognosis of LAPC patients who had received IRE treatment.

In the presence of the competing risk model, apart from age, other factors which were shown to independently predict OS and CSS included tumor site, tumor grade, tumor size, and chemotherapy. Involvement of the vascular structure and tumor size was the predominant feature of the included patients in this study. Gray\'s model also consolidated the determinant role of tumor size in predicting CSS in this study. In addition, our study showed that, compared with OS, tumor size weighted more in predicting CSS which was mainly influenced by the inherent characteristics of tumor itself. Tumor grade and tumor site were also proven to be prognostic factors and were included in the stage system in this study, which was in accordance with other similar studies ([@B27], [@B31]). Our analysis supported the prognostic significance of tumor site in predicting OS and indicated that LAPC patients occurring in the head or overlapping sites of the pancreas had a decreasing probability of OS compared with diseases occurring in the body and tail of pancreas. Moreover, tumor grade and tumor site have also displayed prognostic values, which was independent of other important prognostic factors from the TNM stage system in this study. As for chemotherapy combined with IRE, in addition to local disease control by IRE, chemotherapy could adequately control microscopic diseases. Additionally, IRE could also assist chemotherapy delivery to the tumor by disrupting the dense stroma of PC ([@B32], [@B33]). Therefore, the synergistic effect from the combination of chemotherapy and IRE could contribute to a significantly prolonged survival.

Patient counseling and decision-making are based on the prognosis estimated from the individual risk profiles. With the increasing concern for non-cancer-specific mortality, competing risk analyses have been adopted in more and more cancer researches, such as lung cancer, breast cancer, gastric cancer, and head and neck cancer ([@B30], [@B34]--[@B36]). Considering that 23.8% of deaths were caused by competing causes other than primary LAPC, the competing interesting causes were taken into account when the prognosis is evaluated in our study. As far as we know, it was the first time to evaluate the prognostic factors based on the competing risk analysis model for LAPC patients after IRE treatment. Apart from the factors included in the TNM stage system, age, was generally accepted as a determinant of comorbidity, and tumor grade and chemotherapy were both integrated into the present-stage system. The established nomograms displayed higher C-indexes and values of AUC, indicating better discriminatory power in predicting OS, CSS, and NCSS. To further illustrate the clinical use of the established nomograms, the nomograms were validated in the SYSUCC cohort, which was used as an external cohort. The C-indexes of the external cohort were significantly higher than those of the 7th or 8th edition TNM stage system. That is to say, the well-validated nomograms can be used to predict survival of LAPC patients in clinical practice.

The superior power of nomograms in predicting survival may partly be due to the inclusion of additional variables. Moreover, the results of our research which were based on the analyses from a relatively large population-based database were more generable than those from single-center studies. The present study was therefore the first to evaluate prognostic factors based on large cohorts for LAPC patients after IRE. The nomograms, which comprise a few easily obtained predictors, could help doctors make accurate individual prognosis estimates and select groups of patients with different risks of decreased survival after IRE. Patients with high risks of decreased survival, which were suggested by survival estimation of nomograms, could benefit more from adjuvant therapies, including chemotherapy and radiotherapy. Therefore, with this easily used predictive system, diverse risk factors of patients could be assessed by doctors more objectively and precisely. However, rigorous tests and validations with more external cohorts, specially study cohorts from perspective studies, are needed for the established nomograms before they are formally adopted in clinical practice. Finally, a more optimized prognosis estimation would contribute to more specialized personal treatment.

There are some limitations for this study. First, the nomograms were generated from baseline characteristics of LAPC patients. The addition of some potential prognostic variables, such as carbohydrate antigen 19-9, lymph node metastasis, and vascular invasion, which were unavailable in the SEER dataset, may further improve the predictive power of the present-stage system. Second, the nomograms were generated from patients after specific treatment (IRE). They were not suitable for all LAPC patients. Third, the development of chemotherapy would cause the differences and changes in regions or causes along with time. Therefore, the adjustment and perfection of the chemotherapy variables in the nomograms are an important work to do in the future. Although the nomograms were generated from a large population-based database and validated in an external cohort, further wide validation based on other population is still needed to estimate the accuracy of models.

In conclusion, we evaluated cancer-specific and non-cancer-specific deaths in LAPC patients after IRE treatment and established nomograms to specially predict OS, CSS, and NCSS for these patients. The established nomograms exhibited relatively good performance in predicting survival and might facilitate highly tailored patient management in clinical practice.
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